PROCEPT BioRobotics Corporation
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Larry L. Wood
- Full Time Employees
- 756
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 900 Island Drive San Jose CA United States of America 94065
- IPO Date
- Sep 15, 2021
- CIK
- 0001588978
- Website
- procept-biorobotics.com
- Similar Companies
- Business
- PROCEPT BioRobotics Corporation is a surgical robotics company that develops, manufactures, and commercializes image-guided robotic systems and minimally invasive technologies for the treatment of urologic conditions, with a primary focus on benign prostatic hyperplasia (BPH) in the United States and internationally. The company operates in the medical devices segment of the healthcare industry and serves urologists, hospitals, and ambulatory surgery centers seeking advanced, procedure-enabling technologies for BPH and related lower urinary tract symptoms. PROCEPT BioRobotics Corporation was founded in 2008 and is headquartered in Redwood City, California. The company’s core platform is the AquaBeam Robotic System, an advanced, image-guided, heat-free surgical robotic system designed to deliver Aquablation therapy, a minimally invasive waterjet-based resection of prostate tissue for the treatment of lower urinary tract symptoms due to BPH. AquaBeam integrates real-time imaging, robotic navigation, and automated waterjet ablation to enable precise, surgeon-controlled yet robotically executed tissue removal, aiming to improve functional outcomes while reducing complications such as sexual dysfunction and incontinence associated with traditional BPH surgeries. The company generates revenue from capital equipment sales of AquaBeam consoles; single-use handpieces and consumables; software and imaging integration; and related service, maintenance, and training contracts. In addition, PROCEPT develops and commercializes Aquablation therapy protocols and clinical programs that support adoption across a range of prostate sizes and patient risk profiles. PROCEPT is also advancing the HYDROS Robotic System, its next-generation image-guided robotic platform that builds on the AquaBeam technology to expand the company’s capabilities in urologic surgery and enhance workflow, efficiency, and clinical performance for BPH procedures. HYDROS is designed as a major platform upgrade, offering improved ergonomics, software, and hardware architecture to support broader utilization and long-term scalability across the company’s installed base. Beyond capital systems, the company’s product and service portfolio includes clinical education and training programs; digital planning and visualization tools; and post-market data collection and registry initiatives that support evidence generation and health economic positioning with providers and payers. In recent years, PROCEPT BioRobotics has registered significant commercial expansion, reporting strong year-over-year revenue growth driven by higher AquaBeam system placements, increased utilization, and growing recurring revenue from disposables and services. For full-year 2024, the company reported substantial revenue growth versus 2023, alongside continued gross margin expansion supported by scale efficiencies, higher average selling prices, and improved overhead absorption. The installed base of systems in the United States has expanded rapidly, surpassing 500 units by late 2024 and moving toward 600 systems in 2025, reflecting deepening penetration in key urology and surgical centers. Major recent strategic developments include U.S. FDA 510(k) clearance of the HYDROS Robotic System in 2024, marking the first significant platform advancement beyond AquaBeam and positioning the company for a multi-year upgrade and expansion cycle. The company also obtained FDA Investigational Device Exemption (IDE) approval for the WATER IV PCa pivotal study in prostate cancer, aiming to extend Aquablation or related waterjet technology into oncologic indications and broaden its addressable urology market beyond BPH. Operationally, PROCEPT continues to scale manufacturing, service infrastructure, and commercial organizations in the United States and internationally, while investing in clinical trials and health economic studies to support guideline inclusion, reimbursement expansion, and global market access. In 2025, the company announced the appointment of Larry Wood as Chief Executive Officer, signaling ongoing leadership evolution to support its next phase of global growth.
PROCEPT BioRobotics® Advances Prostate Cancer Program with WATER IV Study Enrollment Completion and Expanded IDE Approval
AUA Guidelines Strengthen Recommendation for Aquablation® Therapy
PROCEPT BioRobotics Corporation (PRCT) Presents at Bank of America Global Healthcare Conference 2026 Transcript
PROCEPT BioRobotics® to Attend Three Upcoming Investor Conferences in May & June
PROCEPT BioRobotics Corporation (PRCT) Q1 2026 Earnings Call Transcript
PROCEPT BioRobotics Corporation (PRCT) Reports Q1 Loss, Tops Revenue Estimates
PROCEPT BioRobotics Reports First Quarter 2026 Financial Results
Chicago Capital Doubles Down on PROCEPT BioRobotics, Adds $27 Million in Stock
Securities Fraud Investigation Into PROCEPT BioRobotics Corporation (PRCT) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
PROCEPT BioRobotics Corporation (PRCT) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
Securities Fraud Investigation Into PROCEPT BioRobotics Corporation (PRCT) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
PROCEPT BioRobotics® to Report First Quarter 2026 Financial Results on April 29, 2026
Reviewing PROCEPT BioRobotics (NASDAQ:PRCT) & OPKO Health (NASDAQ:OPK)
PROCEPT BioRobotics Corporation $PRCT Shares Acquired by SG Americas Securities LLC
PRCT: $50.2M ADJUSTED EBITDA LOSS VS. $35M PROJECTED -- LEVI & KORSINSKY, LLP INVESTIGATES
Procept BioRobotics: An Undervalued Surgical Robotics Growth Story
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PROCEPT BioRobotics Corporation - PRCT
PRCT: GUIDED $325.5M, HID PRICING HEADWIND -- LEVI & KORSINSKY, LLP INVESTIGATES
PRCT: $50.2M ADJUSTED EBITDA LOSS VS. $35M PROJECTED -- LEVI & KORSINSKY, LLP INVESTIGATES
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PROCEPT BioRobotics Corporation - PRCT